Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database

Yekeduz E., Erturk I., Tural D., Karadurmus N., Karakaya S., Hizal M., ...More

FUTURE ONCOLOGY, vol.17, pp.4861-4869, 2021 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 17
  • Publication Date: 2021
  • Doi Number: 10.2217/fon-2021-0717
  • Journal Name: FUTURE ONCOLOGY
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, CINAHL, EMBASE, MEDLINE
  • Page Numbers: pp.4861-4869
  • Keywords: immunotherapy, kidney cancer, nivolumab, renal cell carcinoma, MANAGEMENT, EVEROLIMUS, SUNITINIB, OUTCOMES, THERAPY, BRAIN
  • Hacettepe University Affiliated: Yes

Abstract

Lay abstract Nivolumab is an immune checkpoint inhibitor (ICI) that blocks the communication between T cells and cancer cells and instead activates T cells to fight against cancer. Metastatic renal cell carcinoma (mRCC) is one of the most susceptible tumors to ICIs. The Checkmate 025 trial showed the efficacy of nivolumab in patients with previously treated mRCC. In this real-world study, 173 patients with mRCC were treated with nivolumab in the second line and beyond. Nivolumab was effective in the real-world setting without additional safety concerns.